|
|
||||||||
J Thorac Cardiovasc Surg 2006;131:1161-1166
© 2006 The American Association for Thoracic Surgery
Cardiothoracic Transplantation |
a Department of Cardiac Surgery, Institute for Clinical Immunology, Friedrich-Alexander University Erlangen-Nuernberg, Erlangen, Germany
b Department of Medicine III, Institute for Clinical Immunology, Friedrich-Alexander University Erlangen-Nuernberg, Erlangen, Germany
c Department of Cardiothoracic Surgery, Deutsches Herzzentrum, Berlin, Germany
Received for publication September 20, 2005; revisions received December 6, 2005; accepted for publication January 13, 2006. * Address for reprints: Stephan M. Ensminger, MD, DPhil, Department of Cardiac Surgery, Friedrich-Alexander University Erlangen-Nuernberg, Krankenhausstrasse 12, 91054 Erlangen, Germany (Email: stephan.ensminger{at}herz.imed.uni-erlangen.de).
BACKGROUND: Transplant arteriosclerosis, the hallmark feature of chronic rejection, is still the major limiting factor for the long-term success of heart transplantation. Platelets have been implicated to play a role in the pathogenesis of this disease. Therefore the aim of this study was to investigate whether platelet inhibition alone has a positive effect on the development of transplant arteriosclerosis.
METHODS: Fully major histocompatibility complexmismatched C57BL/6 (H2b) donor aortas were transplanted into CBA (H2k) recipients, and mice received different doses (1, 10, and 20 mg/kg) of clopidogrel or control saline as a daily intraperitoneal injection for 30 days. Blood was analyzed on days 2, 7, 14, and 30 by using a platelet aggregation test (adenosine diphosphate) for effectiveness of the treatment. Grafts were analyzed by means of histology and morphometry on day 30 after transplantation.
RESULTS: When mice were treated daily with 1 mg/kg clopidogrel in the absence of any other immunosuppression, transplant arteriosclerosis was significantly reduced compared with that seen in saline-treated control animals (intimal proliferation of 66% ± 9% [1 mg/kg clopidogrel] vs 77% ± 5% [control], n = 7, P
.03). Daily application of 10 mg/kg and 20 mg/kg clopidogrel also significantly reduced the development of transplant arteriosclerosis compared with that seen in control animals (intimal proliferation of 61% ± 11% [10 mg/kg clopidogrel] vs 54% ± 10% [20 mg/kg clopidogrel] vs 77% ± 5% [control], n = 8, P
.003). There was, however, no additional beneficial effect when compared with mice treated with 1 mg/kg clopidogrel (P = .06). Isografts did not show any signs of vascular lesions on day 30 after transplantation.
CONCLUSION: These results demonstrate that monotherapy with clopidogrel can effectively reduce the formation of transplant arteriosclerosis in a murine aortic allograft model.
This article has been cited by other articles:
![]() |
R. N. Mitchell and P. Libby Vascular Remodeling in Transplant Vasculopathy Circ. Res., April 13, 2007; 100(7): 967 - 978. [Abstract] [Full Text] [PDF] |
||||
![]() |
Chia Shu Hui, C. S. McLachlan, and M. Moursi Can Clopidogrel Monotherapy Influence Vascular Remodeling? Vascular and Endovascular Surgery, April 1, 2007; 41(2): 165 - 166. [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |